Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.

ABSTRACT:

Purpose

This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings.

Methods

Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning the second quarter of 2020 through the first quarter of 2023 were retrospectively analyzed in this pharmacovigilance investigation. This study focuses on employing subgroup analysis to monitor rimegepant drug safety. Descriptive analysis was employed to examine clinical characteristics and concomitant medication of adverse event reports associated with rimegepant, including report season, reporter country, sex, age, weight, dose, and frequency, onset time, et al. Correlation analysis, including techniques such as violin plots, was utilized to explore relat

SUBMITTER: Hu JL 

PROVIDER: S-EPMC11460227 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature